Ahlstrom has introduced Acti V BIO, a specialty paper formulated for release liners in pressure-sensitive adhesive (PSA) healthcare products.
The company engineered the paper alongside Solventum, a multinational healthcare manufacturer that utilises PSA technologies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Solventum outlined the testing protocols and bioburden benchmarks necessary to satisfy compliance standards in regulated healthcare sectors.
The material targets medical goods subject to rigorous sterilisation and contamination limits.
Projected end uses include surgical tapes, transdermal patches, wound care dressings, and wearable or diagnostic devices featuring adhesive components shielded by peel-off liners.
The release base paper enters Ahlstrom’s proprietary Acti V portfolio as a controlled-bioburden grade, maintaining microbiological standards and stable performance across the medical supply chain.
Solventum sterilisation and microbiology global senior director David Brodersen said: “We worked with Ahlstrom to reduce bioburden variability at the material level, helping manufacturers maintain greater consistency in finished product bioburden and reduce the potential for unexpected microbial challenges to validated sterilisation processes.
“Our collaboration demonstrates the value of bringing together material science expertise and healthcare application knowledge to address evolving industry requirements.”
To minimise impurities and facilitate downstream product sterilisation, production pairs adjusted material specifications with plant-level contamination barriers and manufacturing protocols.
Microbial counts are evaluated prior to sterilisation through accredited test protocols.
These assessments track the efficacy of upstream hygiene measures and assist conversion facilities in preparing final sterilisation procedures.
Ahlstrom release liners sustainability and marketing product head Marco Martinez said: “Acti‑V BIO reflects our commitment to developing innovative specialty materials that help customers meet increasingly stringent healthcare requirements.
“This product is the result of a comprehensive development programme focused on supporting contamination control in demanding healthcare customer applications while preserving the sustainability advantages of renewable cellulose-based materials.”
